Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis

Cancer Biotherapy & Radiopharmaceuticals
Zeynep Gozde OzkanCuneyt Turkmen

Abstract

Although some algorithms are defined for the treatment of advanced hepatocellular carcinoma (HCC), the expected survival cannot be prolonged as it is intended. Treatment options for this group of patients are limited. Radioembolization with yttrium-90 (Y-90) microspheres is a new treatment modality, which has also been used in advanced HCC patients. In this study, the authors aimed to assess the efficiency of radioembolization with Y-90 microspheres and evaluate prognostic factors that influence the survival in HCC patients. The authors retrospectively evaluated data of 29 HCC patients who had radioembolization with Y-90 resin or glass microspheres between May 2009 and January 2014. Patient survival was evaluated by using the Kaplan-Meier method. Subgroup comparisons in terms of age, sex, prior treatment status before radioembolization, tumor burden, time between HCC diagnosis and radioembolization, alpha fetoprotein (AFP) level before radioembolization, presence of portal vein thrombosis (PVT), hepatopulmonary shunt ratio, extrahepatic disease burden, multifocality, bilaterality, Eastern Cooperative Oncology Group (ECOG), Child-Pugh, and Barcelona Clinic Liver Cancer (BCLC) status were performed to evaluate prognostic factors ...Continue Reading

References

Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Nov 22, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Laura M KulikRiad Salem
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Jan 9, 2010·International Journal of Radiation Oncology, Biology, Physics·Mercedes IñarrairaeguiBruno Sangro
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S JelicUNKNOWN ESMO Guidelines Working Group
Jul 6, 2010·Journal of Vascular and Interventional Radiology : JVIR·Mercedes IñarrairaeguiBruno Sangro
Aug 10, 2010·Journal of Vascular and Interventional Radiology : JVIR·Andrea Lan TsaiBert H O'Neil
Nov 3, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Philip HilgardGerald Antoch
Mar 5, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN American Association for the Study of Liver Diseases
May 28, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Bruno SangroUNKNOWN European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY)
Jul 28, 2011·European Journal of Nuclear Medicine and Molecular Imaging·Bieke LambertLuc Defreyne
Aug 6, 2011·Journal of Hepatology·Bruno SangroJose I Bilbao
Dec 12, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Belen Gil-AlzugarayBruno Sangro

❮ Previous
Next ❯

Citations

Aug 28, 2016·Journal of Vascular and Interventional Radiology : JVIR·Maureen P Kohi
Sep 14, 2016·World Journal of Gastroenterology : WJG·Stephen L ChanKenneth S H Chok

❮ Previous
Next ❯

Software Mentioned

Siemens

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.